ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology company. The agreement provides Ro with rights to ChromaDex’s patented nicotinamide riboside ingredient Niagen®, the sole active ingredient in Tru Niagen®, for specially formulated Roman products.

Read more here.